Statements (107)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:biotechnology
|
gptkbp:CEO |
gptkb:Binish_Chudgar
|
gptkbp:country |
gptkb:India
|
gptkbp:focusArea |
gptkb:allergy
antibiotics cardiology immunology infectious diseases neurology oncology pediatrics psychiatry endocrinology medical devices orthopedics personal care products transplantation vaccines women's health critical care dermatology gastroenterology hepatology nephrology ophthalmology pain management rheumatology urology gynecology hematology vitamins diagnostics autoimmune diseases antifungals antiparasitics antivirals corticosteroids immunosuppressants supplements respiratory men's health veterinary medicines antipsychotics nutraceuticals anticonvulsants herbal medicines hormone replacement therapy anticoagulants anti-infectives antihistamines antihypertensives bronchodilators diabetology metabolic disorders animal health products biologicals topicals antidepressants OTC products injectables oral liquids oral solids cosmeceuticals anxiolytics antidiabetics antimalarials antirheumatics contraceptives ampoules suppositories vials analgesics sachets formulations antineoplastics API (Active Pharmaceutical Ingredients) antigout agents antimigraine agents antiparkinsonian agents antiplatelets antithyroid agents cytotoxics fertility agents inhalers lipid-lowering agents ophthalmics plasma products pre-filled syringes transdermals |
gptkbp:foundedIn |
1984
|
gptkbp:founder |
Hasmukh Chudgar
|
gptkbp:headquartersLocation |
gptkb:Ahmedabad
|
https://www.w3.org/2000/01/rdf-schema#label |
Intas Pharmaceuticals
|
gptkbp:industry |
pharmaceuticals
|
gptkbp:manufacturingFacilities |
gptkb:Europe
gptkb:India gptkb:Mexico gptkb:UK |
gptkbp:market |
global
|
gptkbp:numberOfEmployees |
over 10,000
|
gptkbp:products |
biosimilars
generic medicines |
gptkbp:revenue |
over $2 billion (2022)
|
gptkbp:subsidiary |
gptkb:Accord_Healthcare
|
gptkbp:website |
https://www.intaspharma.com/
|
gptkbp:bfsParent |
gptkb:Erythropoietin
|
gptkbp:bfsLayer |
6
|